= Members Only
The ACT podcast program, ToxChats ©, reports on cutting-edge news in toxicological research from around the globe. The program features interviews with experts and a review of the current advances. Tune into the podcast using a internet connection to learn about breakthroughs and regulatory developments in toxicological research and more.
The views and opinions expressed in this podcast are those of the guest speakers and do not necessarily reflect the official policy or position of the American College of Toxicology. For the College’s policy on the ethical treatment of animals in research, please see our comprehensive policy statement at www.actox.org.
Episode 8: Regulation of E-Cigarettes
In this episode, Dr. Arianne Motter, a toxicologist with the Center for Drug Evaluation and Research at the US Food and Drug Administration, discusses the complex regulation of e-cigarettes at the FDA and the issues that toxicologists face when evaluating the potential these products have to reduce harm and the risk of tobacco-related disease. At the time of recording, Dr. Motter was a toxicologist with the Center for Tobacco Products at the FDA.
Episode 7: The Opioid Epidemic
In this episode of ToxChats, the opioid epidemic was discussed from a preclinical drug development perspective with Dr. Carrie Blum, Associate Director, Toxicology at Sunovion Pharmaceuticals and Dr. Mary Jeanne Kallman, VP and consultant at her own company Kallman Preclinical Consulting LLC.
Episode 6: Unique Identity Podcast
The goal of this podcast was to get an understanding of how ACT is different from other organizations and what makes ACT unique. In this episode, several meeting attendees were interviewed (aka ACT ToxChats stars!) at the 2017 ACT Annual Meeting in Palm Springs California. The individuals were asked about their involvement in ACT, what they think makes ACT unique, and what they love about the organization and the Annual Meeting. Members who have been part of ACT for over two decades, as well as those who have just recently discovered ACT, were among those interviewed.
Episode 5: 2017 ACT Annual Meeting in Palm Springs: Highlights and Preview
Tracey Zoetis, current president of ACT, we will be talking about the upcoming Annual Meeting of ACT in Palm Springs, California, in November.
Episode 4: Biomarkers
The role of biomarkers and their qualification in nonclinical and clinical development is discussed with Dr. William Mattes. Dr. Mattes is Director of the Division of Systems Biology, part of the FDA’s National Center for Toxicological Research in Jefferson, Arkansas.
Episode 3: Microbiome
Dr. Rodney Dietert has authored a number of books on the immune system and extensively published on the topics of noncommunicable diseases, immune dysfunction, and the microbiome. His latest book is titled “The Human Superorganism: How the Microbiome is Revolutionizing the Pursuit of a Healthy Life.” In this podcast, Dr. Dietert discusses the microbiome in the context of nonclinical development of therapeutic drugs.
Episode 2: Oligonucleotide Therapeutics
Oligonucleotide therapeutics are all medications that utilize RNA- or DNA-based techniques as the effective entity. The nonclinical development of these therapeutics presents unique challenges and these are discussed here with Drs. Sven Korte from Covance, Brian Vuillemenot from Genentech and Scott Henry from Ionis Pharmaceuticals, all experts in oligo therapeutic development.
Episode 1: Introduction to the American College of Toxicology
The American College of Toxicology organizes a variety of educational opportunities throughout the year. This year is no different, however in addition to webinars and courses, ACT is launching podcasts. In addition, strategic planning meetings are held every three years to help keep the College stay on track with activities and objectives for the coming years. Current ACT President, Tracey Zoetis, discusses planned activities for this coming year and provides an update on the strategic meeting, which was held in February 2017.